Mode
Text Size
Log in / Sign up
N/A N=158 Randomized Quadruple-blind Treatment

Safety and Effectiveness of PN40082 for Lip Augmentation

Lip Augmentation

Enrolled (actual)
158
Serious AEs
1.9%
Results posted
Jul 2021
Primary outcome: Primary: Change in Overall Lip Fullness Grading Scale — 1.52; 1.53 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PN40082 (Device); Restylane Silk (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Prollenium Medical Technologies Inc.
Primary completion
May 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Overall Lip Fullness Grading Scale
1.52; 1.53
SECONDARY
Treatment Success Lip Fullness Grading Scale
49; 51
SECONDARY
Treatment Success Perioral Lines Severity Scale
14; 12
SECONDARY
Change From Baseline to Visit 4/Month 3 in Overall Lip Fullness Grading Scale
1.37; 1.42
SECONDARY
Change From Baseline to Visit 5/Month 6 in Overall Lip Fullness Grading Scale
1.00; .93

Summary

To compare the safety and efficacy profile of PN40082 versus Restylane Silk Injectable Gel with 0.3% lidocaine (Restylane Silk) for lip augmentation in approximately 158 subjects.

Eligibility Criteria

Inclusion Criteria

  • Men or non-pregnant or non-breastfeeding women over 21 years of age
  • If female and of childbearing potential, a negative urine pregnancy test at Baseline (Day 1) and the subject agrees to use adequate contraception during the study period
  • Has an overall score of very thin, or thin on the LFGS, as agreed upon by the Treating and Evaluating Investigators, and desires at least a 1-point improvement in overall LFGS score; OR Has a Fitzpatrick skin phototype IV, V or VI and has an LFGS score of thick or full, as agreed upon by the Treating and Evaluating Investigators, and desires treatment to the vermilion body of 1 or both lips
  • Willing to give written informed consent

Exclusion Criteria

  • Women who are pregnant, lactating, or planning a pregnancy
  • History of allergy, anaphylaxis or hypersensitivity to injectable hyaluronic acid products, local anesthetics of the amide type such as lidocaine, or to latex, or is planning to undergo desensitization therapy during the study
  • Has lip tattoos, piercings, facial hair, or scars that would interfere with visualization of the lips and perioral area for the effectiveness assessments
  • Has abnormal lip function, with inability to effectively sip water through a straw
  • Has abnormal lip sensation, with inability to feel a 0.4G monofilament or a cotton wisp at any site on the lip
  • Has moderate or severe abnormal lip asymmetry
  • Has any mass formation on the lip
  • Has dentures or any device covering all or part of the upper palate, and/or severe malocclusion or dentofacial or maxillofacial deformities as judged by the Treating Investigator. Subjects planning to undergo extensive dental procedures such as dental implants, multiple tooth extractions, or oral surgery should not participate. Minor dental procedures such as teeth cleaning and repair of caries are not exclusionary
  • Has undergone facial plastic surgery or received permanent facial implants (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene, polyacrylamide, lifting threads) anywhere in the face or neck, or is planning to be implanted with any of these products during the study
  • Has undergone semi-permanent dermal filler treatment (e.g., calcium hydroxylapatite, poly-L-lactic acid) in the lower face (below the orbital rim) within 12 months before enrollment or is planning to undergo such treatment during the study
  • Has undergone facial tissue augmentation with fat injections, botulinum toxin injections in the lower face (below the orbital rim), mesotherapy, or cosmetic procedures in the face or neck (e.g., face-lift, laser, photo-modulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, microneedling, or other ablative procedures) within 9 months before enrollment or is planning to undergo any of these procedures during the study
  • Has used ANY lip filling agents within 12 months of study enrollment (hyaluronic acid products, collagen-based products, etc.)
  • Has used any lip plumping products or devices within 10 days before enrollment or is planning to use such products during the study
  • Has begun using any over-the-counter (OTC) or prescription oral or topical anti wrinkle products for the lips or around the mouth within 90 days before enrollment or is planning to begin using such products during the study (Subjects who have been on a stable regimen of such products for at least 90 days are eligible for the study and must continue their regimen throughout the study.)
  • Is on an ongoing regimen of anticoagulation therapy (e.g., warfarin), thrombolytics, or inhibitors of platelet aggregation or nonsteroidal anti inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen) or other substances known to increase coagulation time (e.g., herbal supplements with garlic or gingko) within 10 days of undergoing study device injections. Subjects who will withhold such therapy for 10 days before AND after any injection session may
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04032977). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search